Bank Of America Corp Oncorus, Inc. Transaction History

Bank Of America Corp

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	SELL	$0.28 - $0.45 $12,310 - $19,784	-43,965 Reduced 98.16%	823 $0
Q4 2022 Feb 10, 2023	BUY	$0.24 - $0.76 $7,686 - $24,339	32,026 Added 250.95%	44,788 $11,000
Q3 2022 Nov 14, 2022	SELL	$0.85 - $1.65 $15,604 - $30,290	-18,358 Reduced 58.99%	12,762 $11,000
Q2 2022 Aug 12, 2022	SELL	$1.04 - $1.86 $27,381 - $48,970	-26,328 Reduced 45.83%	31,120 $39,000
Q1 2022 May 16, 2022	BUY	$1.44 - $5.62 $7,640 - $29,819	5,306 Added 10.18%	57,448 $103,000
Q4 2021 Feb 08, 2022	BUY	$5.03 - $11.63 $210,802 - $487,401	41,909 Added 409.55%	52,142 $275,000
Q3 2021 Nov 15, 2021	SELL	$9.29 - $14.27 $2,257 - $3,467	-243 Reduced 2.32%	10,233 $96,000
Q2 2021 Sep 13, 2021	BUY	$13.3 - $17.3 $139,330 - $181,234	10,476 New	10,476 $144,000

Ticker ONCR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,973,100
Description
Oncorus, Inc., a clinical-stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. The company's lead product candidate is ONCR-177, an intratumorally administered viral immunotherapy based on its oncolytic herpes simplex virus type 1 platform, which is in Phase I clinical trials for treating various canc...

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

Stay updated on Bank Of America Corp with notifications on news.